Related Experiment Video

Updated: Jul 4, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Emerging therapeutic approaches of SHP2-targeted modulators

Xinyu Yang1, Jinbo Xiong1, Bin Yu2,3

  • 1School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Zhengzhou University, Zhengzhou, 450001, China.

Future Medicinal Chemistry
|January 26, 2024
PubMed

Insights

SHP2 regulators show promise as cancer treatments. Both single-drug (monotherapy) and combined therapies are being explored for enhanced efficacy in oncology.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • SHP2 (Src homology 2 domain-containing phosphatase 2) is a key regulator in cellular signaling pathways implicated in cancer.
  • Dysregulation of SHP2 activity is frequently observed in various malignancies, driving tumor growth and progression.
  • Targeting SHP2 offers a potential therapeutic strategy for cancer treatment.

Discussion:

  • Monotherapy utilizing SHP2 inhibitors demonstrates anti-cancer effects by disrupting critical signaling cascades.
  • Combination therapy, integrating SHP2 inhibitors with other anti-cancer agents, may overcome resistance mechanisms and enhance therapeutic outcomes.
  • Evaluating the synergistic effects and optimal combinations is crucial for clinical translation.

Key Insights:

  • SHP2 inhibition can impede tumor cell proliferation and survival.
  • Combination strategies involving SHP2 regulators show potential for broader applicability across different cancer types.
  • Understanding the specific SHP2-dependent pathways in distinct cancers is vital for personalized treatment approaches.

Outlook:

  • Further clinical trials are needed to establish the safety and efficacy of SHP2-targeted therapies.
  • Development of next-generation SHP2 inhibitors with improved selectivity and potency is ongoing.
  • SHP2-targeted therapies hold promise for improving outcomes in difficult-to-treat cancers.
Keywords:
SHP2 modulatorcombination therapyepigenetic inhibitorsimmune checkpoint blockerskinase inhibitorsprotein tyrosine phosphatases

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

377
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167